Canntab Therapeutics Limited
Canntab Therapeutics Limited (CTABF) Revenue
Annual & quarterly revenue history · segment & region breakdown
CTABF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCanntab Therapeutics Limited trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2022.
Revenue trend
2022 – 2010 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-05-31 | $0.00B | +$0.00B | — |
| 2021-05-31 | $0.00B | -$0.00B | -100.00% |
| 2020-05-31 | $0.00B | -$0.00B | -44.44% |
| 2019-05-31 | $0.00B | +$0.00B | +799.99% |
| 2018-05-31 | $0.00B | +$0.00B | — |
| 2017-05-31 | $0.00B | +$0.00B | — |
| 2015-12-31 | $0.00B | +$0.00B | — |
| 2014-12-31 | $0.00B | +$0.00B | — |
| 2013-12-31 | $0.00B | +$0.00B | — |
| 2012-12-31 | $0.00B | -$0.00B | -100.00% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Canntab Therapeutics Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Canntab Therapeutics Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Canntab Therapeutics Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CTABF revenue · 4 questionsCTABF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2022.
▸ Source: FMP · Canntab Therapeutics Limited SEC filings · GAAP · Canntab Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026